KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Arbutus Biopharma (ABUS) over the last 13 years, with Q3 2025 value amounting to $11000.0.

  • Arbutus Biopharma's Depreciation & Amortization (CF) fell 9672.62% to $11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $352000.0, marking a year-over-year decrease of 6638.01%. This contributed to the annual value of $1.4 million for FY2024, which is 28.49% down from last year.
  • Per Arbutus Biopharma's latest filing, its Depreciation & Amortization (CF) stood at $11000.0 for Q3 2025, which was down 9672.62% from $11000.0 recorded in Q2 2025.
  • Arbutus Biopharma's Depreciation & Amortization (CF)'s 5-year high stood at $474000.0 during Q4 2021, with a 5-year trough of $11000.0 in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's median Depreciation & Amortization (CF) value was $355500.0 (recorded in 2024), while the average stood at $335250.0.
  • As far as peak fluctuations go, Arbutus Biopharma's Depreciation & Amortization (CF) skyrocketed by 758.02% in 2023, and later plummeted by 9691.01% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $474000.0 in 2021, then dropped by 27.64% to $343000.0 in 2022, then rose by 7.58% to $369000.0 in 2023, then dropped by 8.94% to $336000.0 in 2024, then tumbled by 96.73% to $11000.0 in 2025.
  • Its last three reported values are $11000.0 in Q3 2025, $11000.0 for Q2 2025, and $330000.0 during Q1 2025.